[{"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-001", "question": "A 43-year-old woman undergoes bilateral DIEP free flap breast reconstruction after nipple-sparing mastectomy. Intraoperatively, the right flap requires an 11-cm venous graft to reach the internal mammary vein, and flow is satisfactory at closure. On postoperative day 3, she develops progressive swelling and violaceous discoloration of the right flap with brisk bleeding on pinprick and Dopplerable arterial signal in the pedicle but no venous signal. Exploration shows a patent arterial anastomosis, a soft flap, and a congested, thrombotic venous graft with limited nearby recipient veins. The contralateral internal mammary and thoracodorsal systems are already occupied by the left flap. Which salvage strategy offers the highest likelihood of durable flap survival?", "options": ["Shortening the flap pedicle with reanastomosis directly to the internal mammary vein after partial flap debulking to reduce reach and venous load", "Use of a retrograde internal mammary vein anastomosis via a newly dissected contralateral internal mammary perforator and interposition venous graft", "Creation of a venous cross-over (cross-chest) anastomosis from the congested flap vein to a contralateral DIEP flap superficial inferior epigastric vein branch", "Conversion of the free flap to a pedicled bipedicled transverse rectus abdominis myocutaneous (TRAM) flap by re-establishing inferior epigastric inflow and rotating the flap on its native pedicle", "Immediate complete flap removal and delayed reconstruction with a latissimus dorsi flap and implant after chemotherapy and radiation are completed"], "answer": "C", "answer_index": 2, "explanation": "Venous cross-over using a contralateral flap vein (often SIEV) is a recognized, high-yield salvage when ipsilateral recipient veins are exhausted, preserving a viable free flap. Shortening the pedicle (A) is not feasible given the reach problem and does not address lack of recipient vein; retrograde IMV with another vein graft (B) adds another long, failure-prone segment. Converting to pedicled TRAM (D) is not realistic once the flap is fully disconnected. Immediate flap loss (E) is last resort and avoids a proven microvascular salvage option.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postoperative day 3 venous congestion signs (swelling, violaceous discoloration, brisk pinprick bleeding, absent venous Doppler despite arterial signal), thrombosed venous graft on exploration with patent artery and soft flap, limited ipsilateral recipient veins, and contralateral internal mammary/thoracodorsal systems occupied by left flap. These point to need for alternative venous outflow without further long grafts or major flap alteration. Main logical issue(s): none; stem provides sufficient details for discriminating options without contradictions or underspecification, supporting C as uniquely best for durable salvage via cross-chest venous anastomosis to contralateral SIEV, a feasible bailout when ipsilaterals are exhausted. Alternatives are inferior: A assumes shortening/debulking overcomes original 11-cm reach deficit (unrealistic); B risks another failure-prone graft; D impossible post-disconnection; E abandons viable flap prematurely. Main medical accuracy issue(s): none; aligns with microvascular surgery standards for DIEP salvage, where venous cross-over preserves free flap viability without converting to pedicled or sacrificing tissue. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postoperative day 3 venous congestion signs (swelling, violaceous discoloration, brisk pinprick bleeding, absent venous Doppler despite arterial signal), thrombosed venous graft on exploration with patent artery and soft flap, limited ipsilateral recipient veins, and contralateral internal mammary/thoracodorsal systems occupied by left flap. These point to need for alternative venous outflow without further long grafts or major flap alteration. Main logical issue(s): none; stem provides sufficient details for discriminating options without contradictions or underspecification, supporting C as uniquely best for durable salvage via cross-chest venous anastomosis to contralateral SIEV, a feasible bailout when ipsilaterals are exhausted. Alternatives are inferior: A assumes shortening/debulking overcomes original 11-cm reach deficit (unrealistic); B risks another failure-prone graft; D impossible post-disconnection; E abandons viable flap prematurely. Main medical accuracy issue(s): none; aligns with microvascular surgery standards for DIEP salvage, where venous cross-over preserves free flap viability without converting to pedicled or sacrificing tissue. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-002", "question": "A 56-year-old man presents with progressive gait ataxia, urinary urgency, and cognitive slowing over 10 months. MRI shows ventriculomegaly out of proportion to mild cortical atrophy, but in addition there is a subtle nodular T1-hypointense, T2-hyperintense lesion in the posterior third ventricle near the aqueduct, with minimal enhancement and no diffusion restriction. Cine phase-contrast MRI demonstrates preserved CSF stroke volume at the cerebral aqueduct. A high-volume lumbar tap test produces only transient, equivocal improvement. Which is the most appropriate next neurosurgical management?", "options": ["Programmable ventriculoperitoneal shunt placement without further workup, given classic normal-pressure hydrocephalus symptoms", "Endoscopic third ventriculostomy with concurrent biopsy of the third ventricular lesion", "Endoscopic biopsy and possible debulking of the third ventricular lesion without CSF diversion, followed by observation", "Stereotactic radiosurgery targeted to the third ventricular lesion followed by reassessment of hydrocephalus", "External lumbar drainage trial over 72 hours before deciding on shunt placement"], "answer": "B", "answer_index": 1, "explanation": "The combination of ventriculomegaly and a small obstructive-appearing lesion near the aqueduct suggests a secondary obstructive hydrocephalus rather than idiopathic NPH; ETV addresses obstruction and allows tissue diagnosis for a possible low-grade tumor or colloid-like lesion. Shunting alone (A, E) ignores a likely focal obstructive cause and risks shunt dependence. Biopsy alone (C) does not treat hydrocephalus. SRS (D) is premature without histology and does not immediately relieve CSF obstruction.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: Progressive gait ataxia, urinary urgency, cognitive slowing (NPH triad); ventriculomegaly disproportionate to mild cortical atrophy; subtle nodular T1-hypointense, T2-hyperintense lesion in posterior third ventricle near aqueduct with minimal enhancement and no diffusion restriction; preserved CSF stroke volume on cine phase-contrast MRI at aqueduct (suggesting patent aqueduct, no obstruction); transient, equivocal improvement after high-volume lumbar tap.\\nMain logical issue(s): Multiple answers defensible as best (M)—B (ETV + biopsy, assuming lesion causes obstruction despite preserved flow), E (external lumbar drainage trial for equivocal NPH, treating as communicating hydrocephalus), and possibly C (biopsy/debulking without diversion, addressing lesion then observing)—stem underspecified (U) on lesion's causative role given preserved flow, requiring unstated assumption of partial obstruction to favor B uniquely; allows >1 reasonable best next step.\\nMain medical accuracy issue(s): Keyed B assumes secondary obstructive hydrocephalus from lesion, but preserved aqueductal CSF stroke volume contradicts obstruction per standard interpretation (reduced flow indicates blockage; preserved suggests communicating like idiopathic NPH). Promotes ETV for non-obstructive case, inconsistent with guidelines where ETV is for obstructive hydrocephalus; misleads on CSF flow assessment and management.\\nMinimal fix: Change stem's 'preserved CSF stroke volume' to 'reduced CSF stroke volume' to indicate obstruction, making B the unambiguous best and medically accurate.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: Progressive gait ataxia, urinary urgency, cognitive slowing (NPH triad); ventriculomegaly disproportionate to mild cortical atrophy; subtle nodular T1-hypointense, T2-hyperintense lesion in posterior third ventricle near aqueduct with minimal enhancement and no diffusion restriction; preserved CSF stroke volume on cine phase-contrast MRI at aqueduct (suggesting patent aqueduct, no obstruction); transient, equivocal improvement after high-volume lumbar tap.\nMain logical issue(s): Multiple answers defensible as best (M)—B (ETV + biopsy, assuming lesion causes obstruction despite preserved flow), E (external lumbar drainage trial for equivocal NPH, treating as communicating hydrocephalus), and possibly C (biopsy/debulking without diversion, addressing lesion then observing)—stem underspecified (U) on lesion's causative role given preserved flow, requiring unstated assumption of partial obstruction to favor B uniquely; allows >1 reasonable best next step.\nMain medical accuracy issue(s): Keyed B assumes secondary obstructive hydrocephalus from lesion, but preserved aqueductal CSF stroke volume contradicts obstruction per standard interpretation (reduced flow indicates blockage; preserved suggests communicating like idiopathic NPH). Promotes ETV for non-obstructive case, inconsistent with guidelines where ETV is for obstructive hydrocephalus; misleads on CSF flow assessment and management.\nMinimal fix: Change stem's 'preserved CSF stroke volume' to 'reduced CSF stroke volume' to indicate obstruction, making B the unambiguous best and medically accurate.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-003", "question": "A 68-year-old man with cT3N1M0 distal esophageal adenocarcinoma receives neoadjuvant chemoradiation with carboplatin/paclitaxel and 50.4 Gy in 28 fractions using IMRT. He has severe baseline interstitial lung disease (UIP pattern) with DLCO 35% predicted. At multidisciplinary review before simulation, the radiation oncologist must choose a planning goal that most reduces the risk of fatal radiation pneumonitis while still allowing adequate target coverage. Which constraint is most critical to prioritize in this scenario?", "options": ["Mean lung dose (MLD) <10 Gy, even if heart V40 increases modestly", "Total lung V20 <20%, accepting an MLD up to 15 Gy", "Ipsilateral lung V30 <15% with no specific constraint on contralateral lung", "Total lung V5 <40% while relaxing V20 and MLD constraints", "Heart V30 <30% with no further reduction in lung dose beyond standard constraints"], "answer": "A", "answer_index": 0, "explanation": "In patients with severe underlying ILD, data show the mean lung dose is the best single predictor of lethal pneumonitis; keeping MLD as low as possible (often <10 Gy) is paramount, even if cardiac doses increase somewhat. V20 (B) is important but less predictive in ILD compared with MLD. Ipsilateral V30 constraints (C) and V5 (D) are less strongly tied to high-grade pneumonitis. Prioritizing heart sparing (E) over lung constraints is inappropriate in a patient at extreme pulmonary risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Severe interstitial lung disease (UIP pattern) with DLCO 35% predicted in a 68-year-old man receiving neoadjuvant chemoradiation (carboplatin/paclitaxel + 50.4 Gy IMRT) for distal esophageal adenocarcinoma; need to prioritize planning goal reducing fatal radiation pneumonitis risk while maintaining target coverage. These drive emphasis on minimizing lung dose in high-risk ILD patient, where mean lung dose (MLD) is the strongest predictor of lethal pneumonitis per evidence. Main logical issue(s): None; stem provides sufficient details for discriminating A as unique best, with options clearly differentiated by relevance to ILD-specific risks. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., ASTRO/ESTRO) emphasizing MLD <10 Gy in ILD to mitigate pneumonitis, even tolerating modest heart dose increases; V20, V5, V30 less predictive in this context; heart sparing secondary. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'based on recent meta-analyses' to rationale for emphasis, but unnecessary.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Severe interstitial lung disease (UIP pattern) with DLCO 35% predicted in a 68-year-old man receiving neoadjuvant chemoradiation (carboplatin/paclitaxel + 50.4 Gy IMRT) for distal esophageal adenocarcinoma; need to prioritize planning goal reducing fatal radiation pneumonitis risk while maintaining target coverage. These drive emphasis on minimizing lung dose in high-risk ILD patient, where mean lung dose (MLD) is the strongest predictor of lethal pneumonitis per evidence. Main logical issue(s): None; stem provides sufficient details for discriminating A as unique best, with options clearly differentiated by relevance to ILD-specific risks. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., ASTRO/ESTRO) emphasizing MLD <10 Gy in ILD to mitigate pneumonitis, even tolerating modest heart dose increases; V20, V5, V30 less predictive in this context; heart sparing secondary. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'based on recent meta-analyses' to rationale for emphasis, but unnecessary.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-004", "question": "A 63-year-old woman undergoes right upper lobectomy via VATS for a 2.8-cm peripheral squamous cell carcinoma. On postoperative day 5 she develops acute dyspnea and subcutaneous emphysema. Chest CT shows a large posterior membranous tracheal defect 2 cm above the carina communicating with a loculated right pleural air collection. Bronchoscopy confirms a 1.5-cm full-thickness laceration with necrotic edges in a fragile, steroid-exposed airway. The right main bronchus is intact; there is no mediastinitis and she is hemodynamically stable but ventilator dependent. Which operative strategy provides the best chance of durable repair and respiratory recovery?", "options": ["Primary end-to-end tracheal resection with anastomosis and neck flexion, without tissue interposition", "Right posterolateral thoracotomy with direct tracheal defect closure reinforced by a pedicled intercostal muscle flap", "Cervical approach with placement of a covered tracheal stent and no open repair", "Right thoracotomy with tracheal defect closure buttressed by a pedicled latissimus dorsi flap and distal tracheostomy below the repair", "Clamshell thoracotomy with carinal resection and reconstruction to isolate the injured segment"], "answer": "B", "answer_index": 1, "explanation": "A posterior distal tracheal laceration communicating with the ipsilateral pleura after lobectomy is best approached via thoracotomy with direct repair and vascularized intercostal muscle buttress, preserving remaining lung and avoiding extensive resection. Circumferential resection (A, E) is excessive and risky in a fragile airway. Covered stenting alone (C) in a full-thickness laceration with necrotic edges risks dehiscence and mediastinitis. Latissimus flap plus distal tracheostomy (D) is more morbid and generally unnecessary compared with intercostal muscle reinforcement.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving unique best answer: Posterior membranous tracheal defect 2cm above carina, 1.5cm full-thickness laceration with necrotic edges in fragile steroid-exposed airway, communication with loculated right pleural air collection post-lobectomy, intact right main bronchus, no mediastinitis, hemodynamically stable but ventilator-dependent. These indicate need for direct repair with vascularized tissue reinforcement via thoracic approach to address necrosis, fragility, and pleural communication while preserving lung function. Main logical issue(s): None; stem provides sufficient discriminating details (location, defect characteristics, stability) to identify B as uniquely best, with alternatives excessive (A, E), insufficient (C), or overly morbid (D). Main medical accuracy issue(s): None; aligns with thoracic surgery standards for iatrogenic tracheal injuries, emphasizing buttressed repair over resection or stenting alone in necrotic full-thickness defects to prevent dehiscence/mediastinitis. B reflects current guidelines (e.g., STS/ESTS) for durable repair using pedicled intercostal flap, accessible post-thoracotomy. Alternatives correctly eliminated: A/E risk anastomotic failure in fragile airway; C inadequate for necrosis; D adds unnecessary morbidity. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving unique best answer: Posterior membranous tracheal defect 2cm above carina, 1.5cm full-thickness laceration with necrotic edges in fragile steroid-exposed airway, communication with loculated right pleural air collection post-lobectomy, intact right main bronchus, no mediastinitis, hemodynamically stable but ventilator-dependent. These indicate need for direct repair with vascularized tissue reinforcement via thoracic approach to address necrosis, fragility, and pleural communication while preserving lung function. Main logical issue(s): None; stem provides sufficient discriminating details (location, defect characteristics, stability) to identify B as uniquely best, with alternatives excessive (A, E), insufficient (C), or overly morbid (D). Main medical accuracy issue(s): None; aligns with thoracic surgery standards for iatrogenic tracheal injuries, emphasizing buttressed repair over resection or stenting alone in necrotic full-thickness defects to prevent dehiscence/mediastinitis. B reflects current guidelines (e.g., STS/ESTS) for durable repair using pedicled intercostal flap, accessible post-thoracotomy. Alternatives correctly eliminated: A/E risk anastomotic failure in fragile airway; C inadequate for necrosis; D adds unnecessary morbidity. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-005", "question": "A 72-year-old man with prior left common femoral endarterectomy and iliac stenting presents with limb-threatening ischemia of the left leg (Rutherford class 5). Angiography shows occluded left external iliac stent and a heavily calcified common femoral artery with poor clamp sites. The profunda femoris is patent with robust collaterals; the superficial femoral artery (SFA) is chronically occluded. Aortobifemoral bypass is contraindicated due to prior hostile laparotomy and significant cardiopulmonary comorbidity. Which revascularization strategy most reliably restores durable inflow to the profunda with acceptable operative risk?", "options": ["Endovascular recanalization and relining of the external iliac stent only, without addressing the common femoral artery", "Retroperitoneal ilio-profunda bypass from the ipsilateral common iliac artery to the profunda femoris artery", "Axillo-bifemoral bypass using an 8-mm ringed PTFE graft with proximal hood anastomosis to the axillary artery", "Femoral-femoral crossover bypass from the contralateral common femoral artery to the ipsilateral profunda femoris artery", "Hybrid repair with endovascular iliac stent relining plus open common femoral endarterectomy and patch angioplasty to the profunda origin"], "answer": "E", "answer_index": 4, "explanation": "A hybrid approach-iliac stent relining to restore inflow plus open common femoral endarterectomy/patch to the profunda-directly corrects both inflow and the key outflow vessel while avoiding aortic surgery. Isolated iliac relining (A) leaves the diseased CFA uncorrected. Ilio-profunda bypass (B) is more invasive than necessary in a hostile abdomen. Axillo-bifemoral (C) and fem-fem crossover (D) ignore the ipsilateral inflow lesion and are less durable or anatomically suboptimal in this context.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: occluded left external iliac stent requiring inflow restoration; heavily calcified common femoral artery (CFA) with poor clamp sites needing direct intervention; patent profunda femoris with robust collaterals as primary outflow; chronically occluded SFA; contraindications to aortobifemoral bypass due to hostile abdomen and cardiopulmonary risks. These clues emphasize durable profunda inflow with minimal operative risk, favoring a hybrid strategy addressing both iliac occlusion and CFA disease without major abdominal surgery. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., prior hostile laparotomy, calcified CFA, patent profunda) to eliminate alternatives as less reliable or riskier, supporting E as uniquely best without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current vascular surgery standards (e.g., SVS guidelines) for limb-threatening ischemia in high-risk patients, where hybrid repairs optimize inflow/outflow durability while minimizing invasiveness. Axillo-bifemoral and fem-fem are valid extra-anatomic options but less optimal here due to ignoring ipsilateral lesions and lower long-term patency. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'based on 2023 SVS guidelines' to stem for explicit modernity.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: occluded left external iliac stent requiring inflow restoration; heavily calcified common femoral artery (CFA) with poor clamp sites needing direct intervention; patent profunda femoris with robust collaterals as primary outflow; chronically occluded SFA; contraindications to aortobifemoral bypass due to hostile abdomen and cardiopulmonary risks. These clues emphasize durable profunda inflow with minimal operative risk, favoring a hybrid strategy addressing both iliac occlusion and CFA disease without major abdominal surgery. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., prior hostile laparotomy, calcified CFA, patent profunda) to eliminate alternatives as less reliable or riskier, supporting E as uniquely best without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current vascular surgery standards (e.g., SVS guidelines) for limb-threatening ischemia in high-risk patients, where hybrid repairs optimize inflow/outflow durability while minimizing invasiveness. Axillo-bifemoral and fem-fem are valid extra-anatomic options but less optimal here due to ignoring ipsilateral lesions and lower long-term patency. Minimal fix: Not needed, as item is already unambiguous and accurate; if enhancing, add 'based on 2023 SVS guidelines' to stem for explicit modernity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-006", "question": "A 45-year-old woman with a 1.7-cm left adrenal incidentaloma has mild hypertension and intermittent headaches. She is on a thiazide diuretic. Labs show: K 3.3 mmol/L, plasma aldosterone 15 ng/dL, plasma renin activity 0.1 ng/mL/h (suppressed), and aldosterone-renin ratio (ARR) of 150 (elevated). Confirmatory saline suppression test is borderline. Adrenal vein sampling (AVS) without cosyntropin stimulation reveals: cortisol-corrected aldosterone lateralization index (LI) of 2.2, but contralateral suppression index <0.3. Which is the most appropriate next step in management?", "options": ["Left laparoscopic adrenalectomy, given imaging-concordant unilateral lesion and contralateral suppression", "Continue medical therapy with mineralocorticoid receptor antagonists because lateralization index is below traditional cutoff", "Repeat AVS with cosyntropin stimulation to clarify lateralization before deciding on surgery", "Proceed to partial (cortical-sparing) resection of the left adrenal nodule to preserve adrenal function", "Observation without intervention, as results suggest nonfunctioning incidentaloma"], "answer": "A", "answer_index": 0, "explanation": "Current AVS interpretation emphasizes both lateralization and contralateral suppression; a low contralateral aldosterone/cortisol ratio (<0.3) strongly indicates unilateral disease even with modest LI, especially with concordant imaging and biochemical primary aldosteronism. Medical therapy (B) or observation (E) ignores resectable unilateral disease. Repeating AVS (C) is unnecessary given clear suppression. Partial adrenalectomy (D) is not standard for unilateral aldosterone-producing adenomas and risks recurrence.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 1.7-cm left adrenal incidentaloma with concordant imaging, biochemical evidence of primary aldosteronism (hypokalemia K 3.3 mmol/L, elevated ARR 150, suppressed renin), borderline saline suppression, and AVS showing modest LI 2.2 but strong contralateral suppression <0.3, indicating unilateral left-sided disease despite LI below traditional >4 cutoff. These clues support adrenalectomy (A) as the next step for potentially curable hypertension. Main logical issue(s): none; the vignette provides sufficient details for discriminating a single best option without contradictions or underspecification, as AVS interpretation prioritizes contralateral suppression per current standards. Main medical accuracy issue(s): none; aligns with Endocrine Society guidelines emphasizing contralateral suppression in AVS for subtype classification of primary aldosteronism, even with modest lateralization, making surgery appropriate for unilateral disease. The rationale correctly notes that medical therapy (B) or observation (E) overlooks resectable pathology, repeating AVS (C) is unnecessary, and partial resection (D) is nonstandard. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 1.7-cm left adrenal incidentaloma with concordant imaging, biochemical evidence of primary aldosteronism (hypokalemia K 3.3 mmol/L, elevated ARR 150, suppressed renin), borderline saline suppression, and AVS showing modest LI 2.2 but strong contralateral suppression <0.3, indicating unilateral left-sided disease despite LI below traditional >4 cutoff. These clues support adrenalectomy (A) as the next step for potentially curable hypertension. Main logical issue(s): none; the vignette provides sufficient details for discriminating a single best option without contradictions or underspecification, as AVS interpretation prioritizes contralateral suppression per current standards. Main medical accuracy issue(s): none; aligns with Endocrine Society guidelines emphasizing contralateral suppression in AVS for subtype classification of primary aldosteronism, even with modest lateralization, making surgery appropriate for unilateral disease. The rationale correctly notes that medical therapy (B) or observation (E) overlooks resectable pathology, repeating AVS (C) is unnecessary, and partial resection (D) is nonstandard. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-007", "question": "A 63-year-old man with compensated cirrhosis (Child-Pugh A, MELD 9) has a 2.3-cm hepatocellular carcinoma (HCC) in segment VII adjacent to the right hepatic vein and diaphragm. He has portal hypertension with platelets 70,000/µL, small varices, and HVPG 13 mmHg. Liver function is preserved; he is not yet listed for transplant due to social issues. Which management offers the best balance of long-term oncologic control and hepatic reserve preservation?", "options": ["Open right posterior sectionectomy including segment VII and part of VIII", "Laparoscopic wedge resection of segment VII tumor with Pringle maneuver", "Ultrasound-guided percutaneous radiofrequency ablation (RFA) of the lesion", "Transarterial chemoembolization (TACE) followed by reassessment for ablation or resection", "Listing for liver transplantation without locoregional therapy until a donor becomes available"], "answer": "C", "answer_index": 2, "explanation": "For a solitary ≤3-cm HCC in a cirrhotic liver with significant portal hypertension and thrombocytopenia, percutaneous ablation achieves local control comparable to resection with lower risk of hepatic decompensation. Major or even limited resection (A, B) carries high risk in portal hypertension (HVPG >10 mmHg). TACE (D) is inferior to curative-intent ablation for small lesions. Delayed transplant without bridging (E) risks progression beyond criteria and prevents near-term curative local control.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 63-year-old with compensated cirrhosis (Child-Pugh A, MELD 9), 2.3-cm solitary HCC in segment VII, portal hypertension (HVPG 13 mmHg, platelets 70,000/µL, small varices), preserved liver function, not transplant-listed due to social issues. These indicate early-stage HCC in a patient with significant portal hypertension, prioritizing minimally invasive therapy for oncologic control without risking decompensation.\\nMain logical issue(s), if any: None; the stem provides sufficient details (tumor size/location, liver status, PHT severity) to discriminate options, supporting C as uniquely best for balancing cure and reserve preservation, without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; aligns with BCLC guidelines recommending ablation (e.g., RFA) over resection for small HCC (<3 cm) in cirrhosis with PHT (HVPG >10 mmHg) due to lower morbidity; TACE is adjunctive, not primary for curative intent in this setting; transplant bridging needed but delayed here.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 63-year-old with compensated cirrhosis (Child-Pugh A, MELD 9), 2.3-cm solitary HCC in segment VII, portal hypertension (HVPG 13 mmHg, platelets 70,000/µL, small varices), preserved liver function, not transplant-listed due to social issues. These indicate early-stage HCC in a patient with significant portal hypertension, prioritizing minimally invasive therapy for oncologic control without risking decompensation.\nMain logical issue(s), if any: None; the stem provides sufficient details (tumor size/location, liver status, PHT severity) to discriminate options, supporting C as uniquely best for balancing cure and reserve preservation, without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; aligns with BCLC guidelines recommending ablation (e.g., RFA) over resection for small HCC (<3 cm) in cirrhosis with PHT (HVPG >10 mmHg) due to lower morbidity; TACE is adjunctive, not primary for curative intent in this setting; transplant bridging needed but delayed here.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-008", "question": "A 39-year-old man presents with recurrent pancreatitis and is found to have a 2.5-cm enhancing mass in the pancreatic head that encases the intrapancreatic common bile duct, with upstream dilatation but no vascular involvement. EUS-FNA is nondiagnostic twice. CA 19-9 is normal. IgG4 level is mildly elevated at 180 mg/dL (ULN 135). CT shows a capsule-like rim around the lesion and diffuse, sausage-shaped enlargement of the gland. Which management approach is most appropriate?", "options": ["Trial of high-dose corticosteroids with close radiologic follow-up before considering surgery", "Pancreaticoduodenectomy because focal autoimmune pancreatitis cannot be reliably distinguished from adenocarcinoma", "Repeat EUS-FNA with core needle and flow cytometry to exclude lymphoma", "Observation alone with serial imaging in 6 months given low CA 19-9 and mild symptoms", "ERCP with biliary brushing cytology and stent placement, with surgery only if cytology is positive"], "answer": "A", "answer_index": 0, "explanation": "Imaging findings (capsule-like rim, sausage-shaped gland) and elevated IgG4 strongly suggest type 1 autoimmune pancreatitis; a steroid trial with close monitoring is accepted to avoid unnecessary Whipple when malignancy is not strongly supported. Immediate pancreaticoduodenectomy (B) is premature. Repeat biopsy (C) is less helpful given characteristic features. Observation alone (D) ignores ongoing pancreatitis and biliary obstruction. ERCP cytology (E) has low sensitivity and does not treat underlying inflammatory disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent pancreatitis, 2.5-cm enhancing pancreatic head mass encasing the bile duct with upstream dilatation but no vascular involvement, twice nondiagnostic EUS-FNA, normal CA 19-9, mildly elevated IgG4 (180 mg/dL, ULN 135), and CT findings of capsule-like rim and diffuse sausage-shaped gland enlargement—these strongly suggest type 1 autoimmune pancreatitis (AIP) over malignancy. The question asks for the most appropriate management, implying a diagnostic-therapeutic trial for suspected AIP. Option A (steroid trial with follow-up) fits as it addresses potential AIP while monitoring for resolution, avoiding unnecessary surgery. Alternatives are inferior: B assumes unreliability but ignores diagnostic steroid response; C pursues unlikely lymphoma despite AIP features; D neglects symptoms and obstruction; E focuses on cytology with low sensitivity, missing AIP treatment. No main logical issues; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., ICDC for AIP) recommending steroid trial in characteristic cases to confirm diagnosis and avoid resection. Minimal fix: No edit needed; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include recurrent pancreatitis, 2.5-cm enhancing pancreatic head mass encasing the bile duct with upstream dilatation but no vascular involvement, twice nondiagnostic EUS-FNA, normal CA 19-9, mildly elevated IgG4 (180 mg/dL, ULN 135), and CT findings of capsule-like rim and diffuse sausage-shaped gland enlargement—these strongly suggest type 1 autoimmune pancreatitis (AIP) over malignancy. The question asks for the most appropriate management, implying a diagnostic-therapeutic trial for suspected AIP. Option A (steroid trial with follow-up) fits as it addresses potential AIP while monitoring for resolution, avoiding unnecessary surgery. Alternatives are inferior: B assumes unreliability but ignores diagnostic steroid response; C pursues unlikely lymphoma despite AIP features; D neglects symptoms and obstruction; E focuses on cytology with low sensitivity, missing AIP treatment. No main logical issues; the stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. No main medical accuracy issues; aligns with current guidelines (e.g., ICDC for AIP) recommending steroid trial in characteristic cases to confirm diagnosis and avoid resection. Minimal fix: No edit needed; item is unambiguous and accurate as is.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-009", "question": "A 26-year-old man presents with splenomegaly, hemoglobin 9.8 g/dL, platelets 130,000/µL, and leukocytes 5,200/µL. Peripheral smear shows tear-drop cells and leukoerythroblastosis. Bone marrow biopsy is markedly fibrotic with 1-2% blasts; JAK2, CALR, and MPL mutations are negative; next-generation sequencing reveals an isolated ASXL1 mutation. Cytogenetics are normal. He is transfusion independent but symptomatic from splenomegaly. DIPSS-plus score indicates intermediate-2 risk primary myelofibrosis. His 10/10 HLA-matched sibling donor is available. Which is the most appropriate management strategy?", "options": ["Begin ruxolitinib and defer allogeneic stem cell transplantation until he becomes transfusion dependent", "Proceed to allogeneic stem cell transplantation in first chronic phase despite triple-negative driver status", "Observation with serial monitoring; ASXL1 mutation alone does not justify early transplant", "Splenectomy followed by hydroxyurea cytoreduction to delay transplantation", "Ruxolitinib bridge therapy for 3-6 months to reduce spleen size, then proceed to planned allogeneic transplantation"], "answer": "E", "answer_index": 4, "explanation": "Intermediate-2 risk myelofibrosis in a young patient with an available donor warrants allogeneic transplant; bridging with ruxolitinib can reduce spleen size and improve conditioning tolerance without compromising transplant timing. Deferring transplant (A, C) risks disease progression. Splenectomy (D) before transplant is reserved for select cases due to morbidity. Immediate transplant without JAK inhibitor optimization (B) may lead to worse peri-transplant outcomes in massively enlarged spleens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include young age (26 years), intermediate-2 risk PMF by DIPSS-plus, symptomatic splenomegaly, transfusion independence, triple-negative driver mutations with isolated ASXL1 (high-risk mutation), normal cytogenetics, and available 10/10 HLA-matched sibling donor. These support curative-intent allogeneic SCT as the goal, with ruxolitinib bridging to optimize spleen size and peri-transplant outcomes. Main logical issue(s): none; the vignette provides sufficient details to discriminate E as uniquely best without contradictions or underspecification. Alternatives are inferior: A defers transplant risking progression; B proceeds immediately without spleen optimization, potentially worsening outcomes; C observes despite intermediate risk and symptoms; D adds splenectomy morbidity unnecessarily. Main medical accuracy issue(s): none; aligns with NCCN/EBMT guidelines for transplant-eligible intermediate-2 MF patients, where ASXL1 confers poor prognosis justifying early SCT, and ruxolitinib bridging is standard to reduce spleen burden without delaying transplant. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include young age (26 years), intermediate-2 risk PMF by DIPSS-plus, symptomatic splenomegaly, transfusion independence, triple-negative driver mutations with isolated ASXL1 (high-risk mutation), normal cytogenetics, and available 10/10 HLA-matched sibling donor. These support curative-intent allogeneic SCT as the goal, with ruxolitinib bridging to optimize spleen size and peri-transplant outcomes. Main logical issue(s): none; the vignette provides sufficient details to discriminate E as uniquely best without contradictions or underspecification. Alternatives are inferior: A defers transplant risking progression; B proceeds immediately without spleen optimization, potentially worsening outcomes; C observes despite intermediate risk and symptoms; D adds splenectomy morbidity unnecessarily. Main medical accuracy issue(s): none; aligns with NCCN/EBMT guidelines for transplant-eligible intermediate-2 MF patients, where ASXL1 confers poor prognosis justifying early SCT, and ruxolitinib bridging is standard to reduce spleen burden without delaying transplant. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-010", "question": "A 31-year-old woman with systemic lupus erythematosus, class IV lupus nephritis, and high-titer anti-dsDNA presents with a 4-week history of progressive symmetric lower extremity weakness, areflexia, and sensory loss. NCS/EMG show a demyelinating polyneuropathy consistent with CIDP. She is on prednisone 10 mg daily and hydroxychloroquine. Creatinine is 1.3 mg/dL; she has nephrotic-range proteinuria. Which immunologic treatment strategy best balances disease control and long-term toxicity?", "options": ["High-dose IV methylprednisolone pulses followed by oral prednisone 1 mg/kg for both CIDP and lupus nephritis", "IVIG monthly for CIDP plus increase prednisone to 0.5 mg/kg, with no other agents", "Rituximab-based regimen targeting both CIDP and lupus nephritis with tapering of steroids", "Cyclophosphamide induction followed by azathioprine maintenance for lupus and CIDP", "Plasma exchange for CIDP plus mycophenolate mofetil for lupus nephritis"], "answer": "C", "answer_index": 2, "explanation": "Rituximab has efficacy in both CIDP (especially autoimmune-mediated forms) and proliferative lupus nephritis, allowing steroid sparing and addressing shared B-cell pathogenesis. High-dose steroids alone (A, B) worsen long-term toxicity and may be insufficient for nephritis. Cyclophosphamide (D) carries more gonadal and malignancy risk in a young woman. Plasmapheresis (E) gives transient CIDP benefit but does not control chronic B-cell-driven lupus nephritis as effectively as rituximab-based regimens.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 31-year-old woman with active class IV lupus nephritis (nephrotic proteinuria, Cr 1.3, high anti-dsDNA), concurrent demyelinating polyneuropathy consistent with CIDP, on low-dose prednisone and hydroxychloroquine; question seeks immunologic strategy balancing disease control and long-term toxicity for both conditions. These clues imply need for a steroid-sparing agent effective against shared B-cell/autoimmune pathogenesis without high gonadal/malignancy risks in a young woman. Main logical issue(s), if any: None; stem provides sufficient details for discrimination, with options comparable in scope, allowing unique best selection without contradictions or underspecification. Main medical accuracy issue(s), if any: Rituximab is not first-line for lupus nephritis (per guidelines favoring MMF/cyclophosphamide induction) or CIDP (IVIG/steroids/PLEX preferred initially), but its use in refractory/autoimmune-associated cases and steroid-sparing benefits align with balancing toxicity/control; rationale's efficacy claims are supported by evidence, though LUNAR trial showed no superiority in LN—still clinically sensible off-label. Minimal fix: No edit needed; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 31-year-old woman with active class IV lupus nephritis (nephrotic proteinuria, Cr 1.3, high anti-dsDNA), concurrent demyelinating polyneuropathy consistent with CIDP, on low-dose prednisone and hydroxychloroquine; question seeks immunologic strategy balancing disease control and long-term toxicity for both conditions. These clues imply need for a steroid-sparing agent effective against shared B-cell/autoimmune pathogenesis without high gonadal/malignancy risks in a young woman. Main logical issue(s), if any: None; stem provides sufficient details for discrimination, with options comparable in scope, allowing unique best selection without contradictions or underspecification. Main medical accuracy issue(s), if any: Rituximab is not first-line for lupus nephritis (per guidelines favoring MMF/cyclophosphamide induction) or CIDP (IVIG/steroids/PLEX preferred initially), but its use in refractory/autoimmune-associated cases and steroid-sparing benefits align with balancing toxicity/control; rationale's efficacy claims are supported by evidence, though LUNAR trial showed no superiority in LN—still clinically sensible off-label. Minimal fix: No edit needed; item is unambiguous and accurate as is.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-011", "question": "A 27-year-old woman sustains a severe crush-avulsion injury to her dominant right forearm in an industrial press. There is segmental loss of the ulnar artery, ulnar nerve (6 cm gap at the wrist), and extensive soft-tissue loss over the volar-ulnar forearm with exposed flexor tendons; radial artery and median nerve are intact. Hand perfusion is marginal via the radial artery. Debridement leaves a 12 × 8 cm wound and nonrepairable FDS/FDP to ring and small fingers. Considering function and reconstructive ladder, what is the optimal reconstructive strategy in a single stage?", "options": ["Local rotational fasciocutaneous flap with reversed interpositional saphenous vein graft for ulnar artery and autologous sural nerve cable grafts for ulnar nerve", "Free anterolateral thigh (ALT) flap with flow-through reconstruction of the ulnar artery and nerve coaptation via sural nerve graft", "Split-thickness skin graft over the exposed tendons after tendon shortening and radial artery-only perfusion", "Pedicled groin flap for soft-tissue coverage and delayed ulnar nerve grafting once the wound bed is stable", "Free radial forearm flap from the contralateral limb including cephalic vein for venous outflow and ulnar nerve primary end-to-end repair under tension"], "answer": "B", "answer_index": 1, "explanation": "A free ALT flap can provide robust soft-tissue coverage and can be configured as a flow-through flap to reconstitute the ulnar artery while allowing concurrent ulnar nerve cable grafting, optimizing perfusion and nerve regeneration in one stage. Local rotational flaps (A) are insufficient for the large defect and lack flow-through capabilities. Skin graft alone (C) is inadequate over exposed tendons and does not restore artery/nerve. Staged groin flap (D) delays nerve repair. A contralateral radial forearm flap (E) sacrifices a major artery and cannot provide tension-free primary nerve repair.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Plastic Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe crush-avulsion with 12x8 cm soft-tissue defect, exposed tendons, segmental ulnar artery loss, 6 cm ulnar nerve gap, nonrepairable FDS/FDP to ring/small fingers, and marginal hand perfusion via intact radial artery, emphasizing single-stage reconstruction per reconstructive ladder for optimal function. These necessitate robust coverage, vascular flow-through restoration, and nerve grafting without delaying repair or sacrificing donor sites unnecessarily. Main logical issue(s): none; the stem provides sufficient details to discriminate options, supporting B as uniquely best by addressing all deficits concurrently. Alternatives are inferior: A lacks defect size coverage and flow-through; C inadequately covers tendons and ignores artery/nerve; D delays nerve repair; E sacrifices contralateral artery and imposes nerve tension. Main medical accuracy issue(s): none; aligns with current reconstructive surgery standards (e.g., free fasciocutaneous flaps like ALT for complex forearm defects, flow-through anastomosis for vascular gaps, sural grafts for nerve defects >3 cm), consistent with ASPS guidelines and board-level knowledge. Minimal fix: No edit needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include severe crush-avulsion with 12x8 cm soft-tissue defect, exposed tendons, segmental ulnar artery loss, 6 cm ulnar nerve gap, nonrepairable FDS/FDP to ring/small fingers, and marginal hand perfusion via intact radial artery, emphasizing single-stage reconstruction per reconstructive ladder for optimal function. These necessitate robust coverage, vascular flow-through restoration, and nerve grafting without delaying repair or sacrificing donor sites unnecessarily. Main logical issue(s): none; the stem provides sufficient details to discriminate options, supporting B as uniquely best by addressing all deficits concurrently. Alternatives are inferior: A lacks defect size coverage and flow-through; C inadequately covers tendons and ignores artery/nerve; D delays nerve repair; E sacrifices contralateral artery and imposes nerve tension. Main medical accuracy issue(s): none; aligns with current reconstructive surgery standards (e.g., free fasciocutaneous flaps like ALT for complex forearm defects, flow-through anastomosis for vascular gaps, sural grafts for nerve defects >3 cm), consistent with ASPS guidelines and board-level knowledge. Minimal fix: No edit needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-012", "question": "A 54-year-old man with a 2.2-cm pituitary macroadenoma causing acromegaly undergoes endoscopic endonasal resection. Postoperative day 1 labs show serum sodium 142 mmol/L and urine output 3.5 L/day. On day 7, sodium is 128 mmol/L with serum osmolality 265 mOsm/kg and urine osmolality 600 mOsm/kg; he is clinically euvolemic. Morning cortisol is 15 µg/dL. On day 12, sodium falls to 118 mmol/L despite fluid restriction, and he becomes confused; serum osmolality 250 mOsm/kg, urine osmolality 750 mOsm/kg. MRI shows no new findings. Which mechanism best explains this delayed worsening hyponatremia?", "options": ["Persistent syndrome of inappropriate antidiuretic hormone secretion (SIADH) from hypothalamic neuronal injury", "Triphasic water balance disorder with transition from SIADH phase to late-phase permanent diabetes insipidus", "Cerebral salt wasting due to subclinical subarachnoid hemorrhage during surgery", "Reset osmostat due to chronic hyponatremia from preoperative growth hormone excess", "Glucocorticoid deficiency from delayed postoperative hypopituitarism"], "answer": "A", "answer_index": 0, "explanation": "The typical triphasic pattern after pituitary surgery is early DI, then SIADH-related hyponatremia around days 5-10; persistent, severe, euvolemic hyponatremia with high urine osmolality is most consistent with sustained SIADH. Transition to DI (B) would cause hypernatremia and dilute urine. Cerebral salt wasting (C) would show hypovolemia and high urine sodium but is rare here. Reset osmostat (D) would not present with acute confusion at Na 118. Cortisol deficiency (E) is unlikely with normal morning cortisol.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurological Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Initial mild polyuria (3.5 L/day) with normal Na on day 1 suggests early transient DI; day 7 euvolemic hyponatremia (Na 128) with low serum osmolality (265) and high urine osmolality (600) points to SIADH phase; normal morning cortisol (15 µg/dL) rules out glucocorticoid deficiency; day 12 worsening (Na 118, confusion) despite fluid restriction, with even lower serum osmolality (250) and higher urine osmolality (750), and no MRI changes, indicates persistent inappropriate ADH secretion rather than resolution or transition to DI. Main logical issue(s), if any: None; the vignette provides sufficient discriminating details (euvolemia, osmolalities, timeline, normal cortisol) to identify persistent SIADH as uniquely best, eliminating alternatives like DI transition (B, would cause hypernatremia/dilute urine), hypovolemic CSW (C), stable mild reset osmostat (D), or cortisol deficiency (E). Main medical accuracy issue(s), if any: None; aligns with standard post-pituitary surgery triphasic response knowledge, where SIADH can persist if hypothalamic injury occurs, per neurosurgical and endocrine guidelines. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Initial mild polyuria (3.5 L/day) with normal Na on day 1 suggests early transient DI; day 7 euvolemic hyponatremia (Na 128) with low serum osmolality (265) and high urine osmolality (600) points to SIADH phase; normal morning cortisol (15 µg/dL) rules out glucocorticoid deficiency; day 12 worsening (Na 118, confusion) despite fluid restriction, with even lower serum osmolality (250) and higher urine osmolality (750), and no MRI changes, indicates persistent inappropriate ADH secretion rather than resolution or transition to DI. Main logical issue(s), if any: None; the vignette provides sufficient discriminating details (euvolemia, osmolalities, timeline, normal cortisol) to identify persistent SIADH as uniquely best, eliminating alternatives like DI transition (B, would cause hypernatremia/dilute urine), hypovolemic CSW (C), stable mild reset osmostat (D), or cortisol deficiency (E). Main medical accuracy issue(s), if any: None; aligns with standard post-pituitary surgery triphasic response knowledge, where SIADH can persist if hypothalamic injury occurs, per neurosurgical and endocrine guidelines. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-013", "question": "A 69-year-old man with T2N0M0 glottic squamous cell carcinoma extending to the anterior commissure is planned for definitive radiotherapy. He is a heavy smoker with severe COPD and cannot tolerate prolonged immobilization. The radiation oncologist must choose the optimal fractionation regimen to maximize local control while minimizing acute laryngeal edema and long-term dysphagia. Which regimen best balances these goals?", "options": ["Conventional 2.0 Gy per fraction to 70 Gy over 7 weeks", "Hypofractionated 2.25 Gy per fraction to 63 Gy over 5.6 weeks", "Hyperfractionated 1.2 Gy twice daily to 79.2 Gy total dose", "Concomitant boost regimen with 1.8 Gy daily plus 1.5 Gy second daily fraction in the final 3 weeks", "Stereotactic body radiotherapy (SBRT) 7.5 Gy × 5 fractions to the glottic larynx"], "answer": "B", "answer_index": 1, "explanation": "For early to select T2 glottic cancers, modest hypofractionation (e.g., 2.25 Gy/fraction to ~63 Gy) improves local control with acceptable toxicity and shorter overall treatment time, particularly useful in patients with limited tolerance for prolonged immobilization. Conventional fractionation (A) is effective but less optimal in control and time. Hyperfractionation (C) and concomitant boost (D) increase mucosal toxicity. SBRT (E) for glottic cancer remains investigational with concerns about cartilage necrosis and voice quality.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Radiation Oncology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: T2N0M0 glottic SCC extending to anterior commissure; heavy smoker with severe COPD intolerant to prolonged immobilization; goals to maximize local control while minimizing acute laryngeal edema and long-term dysphagia. These drive selection of a regimen balancing efficacy, toxicity, and treatment duration. The clinical problem asks for optimal RT fractionation in early-stage glottic cancer with patient-specific constraints. Discriminating findings: Tumor stage implies need for definitive RT; COPD limits tolerance for long sessions, favoring shorter regimens; extension to anterior commissure may increase edema risk with aggressive fractionation. Most likely next step: Modest hypofractionation for improved control and brevity. Keyed answer B fits: 2.25 Gy/fx to 63 Gy shortens treatment to 5.6 weeks, supported by evidence for T2 glottic cancers with acceptable toxicity. Alternatives: A is longer (7 weeks), suboptimal for immobilization issues; C increases BID dosing, risking higher mucosal toxicity; D adds boost, elevating edema/dysphagia risk; E is investigational SBRT with cartilage necrosis concerns. No main logical issues: Stem allows unique best (B) without contradictions or underspecification. No main medical accuracy issues: Aligns with NCCN/ASTRO guidelines favoring hypofractionation for select early glottic cases, especially with comorbidities; biologically equivalent dosing maintains control. Minimal fix: None needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: T2N0M0 glottic SCC extending to anterior commissure; heavy smoker with severe COPD intolerant to prolonged immobilization; goals to maximize local control while minimizing acute laryngeal edema and long-term dysphagia. These drive selection of a regimen balancing efficacy, toxicity, and treatment duration. The clinical problem asks for optimal RT fractionation in early-stage glottic cancer with patient-specific constraints. Discriminating findings: Tumor stage implies need for definitive RT; COPD limits tolerance for long sessions, favoring shorter regimens; extension to anterior commissure may increase edema risk with aggressive fractionation. Most likely next step: Modest hypofractionation for improved control and brevity. Keyed answer B fits: 2.25 Gy/fx to 63 Gy shortens treatment to 5.6 weeks, supported by evidence for T2 glottic cancers with acceptable toxicity. Alternatives: A is longer (7 weeks), suboptimal for immobilization issues; C increases BID dosing, risking higher mucosal toxicity; D adds boost, elevating edema/dysphagia risk; E is investigational SBRT with cartilage necrosis concerns. No main logical issues: Stem allows unique best (B) without contradictions or underspecification. No main medical accuracy issues: Aligns with NCCN/ASTRO guidelines favoring hypofractionation for select early glottic cases, especially with comorbidities; biologically equivalent dosing maintains control. Minimal fix: None needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-014", "question": "A 60-year-old man with severe COPD (FEV1 30% predicted) undergoes right pneumonectomy for central squamous cell carcinoma. On postoperative day 3 he develops sudden respiratory distress, hypotension, and jugular venous distention. CXR shows mediastinal shift toward the left (remaining lung side) with hyperinflation and flattened diaphragm. Emergent bronchoscopy reveals no mucus plug. Echocardiogram shows right ventricular dilation and compression of the left atrium. Which is the most likely diagnosis?", "options": ["Postpneumonectomy pulmonary edema of the remaining lung", "Early bronchopleural fistula with tension pneumothorax on the pneumonectomy side", "Acute pulmonary embolism to the left pulmonary artery", "Postpneumonectomy syndrome due to mediastinal shift and bronchial kinking", "Cardiac tamponade from postoperative hemopericardium"], "answer": "D", "answer_index": 3, "explanation": "Postpneumonectomy syndrome is due to excessive mediastinal shift causing kinking/compression of the remaining main bronchus and cardiovascular structures; though classically delayed, it can present early with hyperinflation of the remaining lung and mediastinal shift toward it, leading to RV dilation and LA compression. Pulmonary edema (A) would not explain marked mediastinal shift. Tension pneumothorax on the pneumonectomy side (B) would shift mediastinum away from the remaining lung. Massive PE (C) lacks imaging features of overinflation and shift. Tamponade (E) shows equal chamber pressures but not lung overinflation or shift.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (Contradiction). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the most likely diagnosis in a post-right pneumonectomy patient with acute distress, hypotension, JVD, mediastinal shift toward the remaining (left) lung, hyperinflation with flattened diaphragm, no mucus plug, and echo showing RV dilation with LA compression. Key stem clues: severe COPD, POD3 onset, shift toward remaining lung, remaining lung hyperinflation, RV dilation, LA compression. These fail to drive a unique best answer due to internal inconsistency. Main logical issue: The described mediastinal shift toward the remaining lung side contradicts the hyperinflation and flattened diaphragm (implying remaining lung overexpansion), as lung hyperinflation would displace the mediastinum away from the remaining side, not toward it, rendering the vignette anatomically incoherent and unsolvable. Main medical accuracy issues: Misrepresents postpneumonectomy syndrome, which typically involves shift toward the operated (right) side with delayed onset, not early POD3 presentation with shift toward remaining side; echo findings partially fit but shift direction and timing are inaccurate; rationale incorrectly states tension pneumothorax shifts away from remaining lung, when it would shift toward it. Overall, item contains major errors contradicting standard pathophysiology and anatomy. Minimal fix: Edit stem to 'mediastinal shift toward the right (pneumonectomy side)' to align with postpneumonectomy syndrome and resolve contradiction.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (Contradiction). Verdict on keyed answer: Not uniquely determinable. The clinical problem asks for the most likely diagnosis in a post-right pneumonectomy patient with acute distress, hypotension, JVD, mediastinal shift toward the remaining (left) lung, hyperinflation with flattened diaphragm, no mucus plug, and echo showing RV dilation with LA compression. Key stem clues: severe COPD, POD3 onset, shift toward remaining lung, remaining lung hyperinflation, RV dilation, LA compression. These fail to drive a unique best answer due to internal inconsistency. Main logical issue: The described mediastinal shift toward the remaining lung side contradicts the hyperinflation and flattened diaphragm (implying remaining lung overexpansion), as lung hyperinflation would displace the mediastinum away from the remaining side, not toward it, rendering the vignette anatomically incoherent and unsolvable. Main medical accuracy issues: Misrepresents postpneumonectomy syndrome, which typically involves shift toward the operated (right) side with delayed onset, not early POD3 presentation with shift toward remaining side; echo findings partially fit but shift direction and timing are inaccurate; rationale incorrectly states tension pneumothorax shifts away from remaining lung, when it would shift toward it. Overall, item contains major errors contradicting standard pathophysiology and anatomy. Minimal fix: Edit stem to 'mediastinal shift toward the right (pneumonectomy side)' to align with postpneumonectomy syndrome and resolve contradiction.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-015", "question": "A 67-year-old woman with lifestyle-limiting claudication and rest pain in the right foot has an occluded right common iliac artery and diffuse calcific disease of the ipsilateral external iliac and common femoral arteries. The left iliac system is patent with a prior kissing stent at the aortic bifurcation. Coronary disease and frailty preclude aortobifemoral bypass. Which revascularization option best optimizes long-term patency and limb salvage?", "options": ["Right axillo-femoral bypass using an 8-mm ringed PTFE graft to the common femoral artery", "Endovascular recanalization and stenting of the occluded right common iliac plus external iliac angioplasty", "Femoral-femoral crossover bypass from left common femoral artery to right profunda femoris artery with endarterectomy of the right common femoral", "Endovascular iliac recanalization combined with drug-coated balloon angioplasty of the common femoral artery", "Ilio-femoral bypass from left common iliac artery to right common femoral artery via a retroperitoneal route"], "answer": "C", "answer_index": 2, "explanation": "Given a hostile aorta and existing left iliac stent, fem-fem crossover with CFA endarterectomy to the profunda provides robust inflow and durable outflow while avoiding major aortic surgery. Axillo-femoral bypass (A) has lower long-term patency. Pure endovascular recanalization (B, D) may be limited by heavy CFA calcification and restenosis risk, and CFA is a poor stent target. Ilio-femoral bypass (E) is more invasive and may be technically challenging given the prior kissing stent and comorbidities.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include occluded right common iliac artery, diffuse calcific disease in ipsilateral external iliac and common femoral arteries, patent left iliac system with prior kissing stent at aortic bifurcation, coronary disease and frailty precluding aortobifemoral bypass, and symptoms of lifestyle-limiting claudication with rest pain indicating critical limb ischemia. These support selecting a durable, less invasive revascularization optimizing long-term patency and limb salvage. Option C (femoral-femoral crossover bypass with right common femoral endarterectomy to profunda) leverages patent left inflow, addresses calcific outflow, and avoids major aortic surgery, aligning with vascular guidelines for unilateral iliac occlusive disease. Alternatives are inferior: A has poorer patency; B and D risk restenosis from heavy calcification and suboptimal common femoral stenting; E is more invasive with technical challenges from prior stent. No main logical issues, as the stem allows discrimination of one best option without contradictions or underspecification. No main medical accuracy issues; rationale reflects current SVS guidelines on peripheral artery disease management, emphasizing hybrid approaches for complex lesions in frail patients. Minimal fix: No fix required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include occluded right common iliac artery, diffuse calcific disease in ipsilateral external iliac and common femoral arteries, patent left iliac system with prior kissing stent at aortic bifurcation, coronary disease and frailty precluding aortobifemoral bypass, and symptoms of lifestyle-limiting claudication with rest pain indicating critical limb ischemia. These support selecting a durable, less invasive revascularization optimizing long-term patency and limb salvage. Option C (femoral-femoral crossover bypass with right common femoral endarterectomy to profunda) leverages patent left inflow, addresses calcific outflow, and avoids major aortic surgery, aligning with vascular guidelines for unilateral iliac occlusive disease. Alternatives are inferior: A has poorer patency; B and D risk restenosis from heavy calcification and suboptimal common femoral stenting; E is more invasive with technical challenges from prior stent. No main logical issues, as the stem allows discrimination of one best option without contradictions or underspecification. No main medical accuracy issues; rationale reflects current SVS guidelines on peripheral artery disease management, emphasizing hybrid approaches for complex lesions in frail patients. Minimal fix: No fix required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-016", "question": "A 58-year-old man with a 3.8-cm right thyroid nodule and compressive symptoms undergoes total thyroidectomy. Final pathology shows a 3.8-cm encapsulated follicular-patterned lesion with capsular and focal vascular invasion in 2 of 8 intracapsular vessels, RAS-mutant, no extrathyroidal extension, and no lymph node involvement. According to modern risk stratification and evolving nomenclature, which postoperative management is most appropriate?", "options": ["Classify as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and no further therapy", "Classify as minimally invasive follicular thyroid carcinoma and recommend routine radioactive iodine ablation", "Classify as encapsulated angioinvasive follicular variant papillary thyroid carcinoma and consider RAI only if postoperative thyroglobulin is detectable", "Classify as low-risk differentiated thyroid carcinoma managed with levothyroxine to keep TSH mildly suppressed and no routine RAI", "Classify as high-risk due to vascular invasion and treat with high-dose RAI and aggressive TSH suppression (<0.1 mIU/L)"], "answer": "D", "answer_index": 3, "explanation": "Encapsulated follicular-patterned tumors with limited vascular invasion (≤4 foci) and no extrathyroidal extension are considered low-risk differentiated thyroid carcinomas; current guidelines favor TSH suppression and no routine RAI, particularly in RAS-mutated lesions without nodal disease. NIFTP (A) requires no invasion; this lesion shows both capsular and vascular invasion. Routine RAI (B, E) is excessive for low-risk tumors. Labeling as high-risk (E) is not justified by limited angioinvasion alone. Option C misclassifies the entity and overemphasizes histologic subtype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Endocrine", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 3.8-cm encapsulated follicular-patterned lesion with capsular invasion, limited vascular invasion (2 of 8 intracapsular vessels), RAS mutation, no extrathyroidal extension, and no lymph node involvement, aligning with low-risk differentiated thyroid carcinoma per modern ATA guidelines favoring TSH suppression without routine RAI. Main logical issue(s): None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting D as the unique best choice based on risk stratification emphasizing limited angioinvasion (≤4 foci) not warranting routine RAI or high-risk classification. Main medical accuracy issue(s): None; the item accurately reflects current standards, including evolving nomenclature distinguishing NIFTP (no invasion) from invasive lesions, RAS-mutated low-risk tumors, and guideline-based avoidance of overtreatment in low-risk DTC without nodal disease or ETE. The rationale correctly notes that routine or high-dose RAI is excessive, and misclassification in C is appropriately critiqued. Minimal fix: N/A; the item is already unambiguous and accurate, though adding 'per 2015 ATA guidelines' to the stem could enhance explicitness if desired.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 3.8-cm encapsulated follicular-patterned lesion with capsular invasion, limited vascular invasion (2 of 8 intracapsular vessels), RAS mutation, no extrathyroidal extension, and no lymph node involvement, aligning with low-risk differentiated thyroid carcinoma per modern ATA guidelines favoring TSH suppression without routine RAI. Main logical issue(s): None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting D as the unique best choice based on risk stratification emphasizing limited angioinvasion (≤4 foci) not warranting routine RAI or high-risk classification. Main medical accuracy issue(s): None; the item accurately reflects current standards, including evolving nomenclature distinguishing NIFTP (no invasion) from invasive lesions, RAS-mutated low-risk tumors, and guideline-based avoidance of overtreatment in low-risk DTC without nodal disease or ETE. The rationale correctly notes that routine or high-dose RAI is excessive, and misclassification in C is appropriately critiqued. Minimal fix: N/A; the item is already unambiguous and accurate, though adding 'per 2015 ATA guidelines' to the stem could enhance explicitness if desired.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-017", "question": "A 66-year-old man with long-standing diabetes and peripheral neuropathy presents with chronic mesenteric ischemia symptoms and weight loss. CTA shows high-grade stenoses of both the celiac and superior mesenteric arteries (SMA) with a patent inferior mesenteric artery and extensive collateralization. There is a focal 2.5-cm jejunal stricture with mild upstream dilation but no mass. Intraoperatively, the bowel is patchy but viable; the stricture is firm and fibrotic. Biopsy shows transmural fibrosis without active vasculitis. Which strategy best addresses both symptoms and long-term gut viability?", "options": ["Endovascular stenting of SMA only, leaving celiac stenosis untreated", "Open antegrade aorto-SMA bypass plus segmental resection of the jejunal stricture", "Isolated resection of the jejunal stricture without mesenteric revascularization", "Retrograde iliac-to-SMA bypass only, with no bowel resection to avoid short-bowel risk", "Endovascular stenting of both celiac and SMA followed by observation of the stricture"], "answer": "B", "answer_index": 1, "explanation": "Symptomatic chronic mesenteric ischemia with structural fibrotic jejunal stricture requires both durable inflow restoration and removal of the fixed lesion; open aorto-SMA bypass offers superior long-term patency in multivessel disease, and resection treats the fibrotic stricture. SMA-only stenting (A) or dual-vessel stenting (E) may have higher restenosis and do not resolve fixed fibrosis. Resection alone (C) ignores global ischemia. Retrograde iliac-SMA bypass without resection (D) leaves a mechanical obstruction.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include symptomatic chronic mesenteric ischemia with weight loss, high-grade stenoses of celiac and SMA, patent IMA with extensive collateralization, focal fibrotic jejunal stricture confirmed by biopsy without vasculitis, and intraoperatively viable but patchy bowel. These support the need for both durable revascularization to address multivessel ischemia and resection of the fixed fibrotic stricture to prevent obstruction and ensure long-term gut viability. Main logical issue(s): None; the stem provides sufficient details to discriminate B as uniquely best, with alternatives failing to address either ischemia (C), stricture (A, D, E), or both adequately, without contradictions or underspecification. Main medical accuracy issue(s): None; the approach aligns with current guidelines (e.g., SVS) where open antegrade aorto-SMA bypass is appropriate for multivessel CMI in surgical candidates, offering superior patency over endovascular options (A, E), especially when combined with resection for ischemic stricture; retrograde bypass (D) is valid but inferior without addressing the stricture. Minimal fix: None required, as the item is already unambiguous and accurate; optionally, add 'patient is a good surgical candidate' to the stem for enhanced realism.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include symptomatic chronic mesenteric ischemia with weight loss, high-grade stenoses of celiac and SMA, patent IMA with extensive collateralization, focal fibrotic jejunal stricture confirmed by biopsy without vasculitis, and intraoperatively viable but patchy bowel. These support the need for both durable revascularization to address multivessel ischemia and resection of the fixed fibrotic stricture to prevent obstruction and ensure long-term gut viability. Main logical issue(s): None; the stem provides sufficient details to discriminate B as uniquely best, with alternatives failing to address either ischemia (C), stricture (A, D, E), or both adequately, without contradictions or underspecification. Main medical accuracy issue(s): None; the approach aligns with current guidelines (e.g., SVS) where open antegrade aorto-SMA bypass is appropriate for multivessel CMI in surgical candidates, offering superior patency over endovascular options (A, E), especially when combined with resection for ischemic stricture; retrograde bypass (D) is valid but inferior without addressing the stricture. Minimal fix: None required, as the item is already unambiguous and accurate; optionally, add 'patient is a good surgical candidate' to the stem for enhanced realism.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-018", "question": "A 52-year-old woman with a history of Roux-en-Y gastric bypass 8 years ago presents with refractory iron-deficiency anemia and vague postprandial epigastric pain. EGD and colonoscopy are negative. Capsule endoscopy shows a circumferential, friable lesion in the excluded stomach. CT enterography confirms a 3.5-cm mass in the excluded gastric remnant without metastatic disease. Which surgical approach is most appropriate for oncologic control and access limitations?", "options": ["Laparoscopic transgastric gastroscopy through the gastric pouch with submucosal dissection of the lesion", "Laparoscopic-assisted resection of the excluded stomach mass via gastrotomy in the remnant and wedge resection", "Conversion of the Roux-en-Y gastric bypass to normal anatomy followed by subtotal gastrectomy", "Open completion gastrectomy including the excluded stomach with Roux-en-Y esophagojejunostomy", "Endoscopic ultrasound-guided radiofrequency ablation of the mass via transluminal puncture from the alimentary limb"], "answer": "D", "answer_index": 3, "explanation": "A 3.5-cm circumferential, friable mass in the excluded stomach is highly suspicious for carcinoma; completion gastrectomy provides oncologic resection with appropriate lymphadenectomy, best achieved via open approach given altered anatomy and access. Laparoscopic wedge resection (B) is inadequate for circumferential malignancy. Converting anatomy first (C) adds complexity without oncologic benefit. Transgastric endoscopic resection (A) and RFA (E) are inappropriate for likely invasive carcinoma in an excluded segment.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of Roux-en-Y gastric bypass 8 years prior, refractory iron-deficiency anemia, vague postprandial epigastric pain, negative EGD and colonoscopy, capsule endoscopy revealing a circumferential friable lesion in the excluded stomach, and CT enterography confirming a 3.5-cm mass without metastatic disease. These findings strongly suggest gastric remnant carcinoma, necessitating oncologic resection with consideration for access challenges in altered anatomy. Main logical issue(s): None; the stem is internally consistent, provides discriminating details (e.g., lesion size, location, friability, absence of mets), and allows clear differentiation among options, with D uniquely addressing oncologic control via open completion gastrectomy including lymphadenectomy. Alternatives are inferior: A and E are minimally invasive but inadequate for potential invasive malignancy; B offers insufficient resection for circumferential involvement; C adds unnecessary procedural complexity. Main medical accuracy issue(s): None; the item's logic aligns with current guidelines (e.g., NCCN for gastric cancer), recognizing risks of remnant malignancy post-bypass and the preference for open approaches in complex anatomy for R0 resection and staging. Minimal fix: Not required, as the item is already unambiguous and accurate; optionally, add 'biopsy-confirmed adenocarcinoma' to the stem to explicitly rule out benign etiologies without altering defensibility.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include history of Roux-en-Y gastric bypass 8 years prior, refractory iron-deficiency anemia, vague postprandial epigastric pain, negative EGD and colonoscopy, capsule endoscopy revealing a circumferential friable lesion in the excluded stomach, and CT enterography confirming a 3.5-cm mass without metastatic disease. These findings strongly suggest gastric remnant carcinoma, necessitating oncologic resection with consideration for access challenges in altered anatomy. Main logical issue(s): None; the stem is internally consistent, provides discriminating details (e.g., lesion size, location, friability, absence of mets), and allows clear differentiation among options, with D uniquely addressing oncologic control via open completion gastrectomy including lymphadenectomy. Alternatives are inferior: A and E are minimally invasive but inadequate for potential invasive malignancy; B offers insufficient resection for circumferential involvement; C adds unnecessary procedural complexity. Main medical accuracy issue(s): None; the item's logic aligns with current guidelines (e.g., NCCN for gastric cancer), recognizing risks of remnant malignancy post-bypass and the preference for open approaches in complex anatomy for R0 resection and staging. Minimal fix: Not required, as the item is already unambiguous and accurate; optionally, add 'biopsy-confirmed adenocarcinoma' to the stem to explicitly rule out benign etiologies without altering defensibility.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-019", "question": "A 45-year-old man with newly diagnosed mantle cell lymphoma receives R-CHOP followed by high-dose cytarabine. Six months later, he presents with worsening fatigue. CBC shows Hb 7.5 g/dL, MCV 105 fL, WBC 2,000/µL, platelets 40,000/µL. Bone marrow biopsy shows 18% myeloblasts with multilineage dysplasia and complex cytogenetics including monosomy 7. Flow cytometry is consistent with therapy-related myelodysplastic syndrome evolving toward AML. He has an HCT-CI score of 4 and a matched unrelated donor. Which management approach offers the best chance of long-term survival?", "options": ["Continue R-CHOP for mantle cell lymphoma and start azacitidine for t-MDS", "High-intensity induction chemotherapy with 7+3 followed by allogeneic stem cell transplantation in first remission", "Azacitidine plus venetoclax for cytoreduction, then allogeneic stem cell transplantation when feasible", "Supportive care only with transfusions and growth factors due to high transplant risk", "Immediate reduced-intensity allogeneic transplantation without further cytoreduction"], "answer": "C", "answer_index": 2, "explanation": "Therapy-related MDS/AML with complex karyotype has poor prognosis; hypomethylating agent plus venetoclax can achieve remissions with better tolerability than intensive 7+3 in a comorbid patient, allowing subsequent allogeneic transplant for potential cure. Continuing lymphoma chemo (A) ignores aggressive secondary myeloid disease. High-intensity induction (B) risks excess toxicity given HCT-CI 4. Supportive care alone (D) is palliative. Immediate RIC transplant without cytoreduction (E) in 18% blasts is associated with high relapse and graft failure rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include therapy-related MDS/AML with 18% blasts, multilineage dysplasia, complex cytogenetics (monosomy 7), HCT-CI score of 4 indicating moderate comorbidity risk, and availability of a matched unrelated donor. These support cytoreduction with azacitidine plus venetoclax (C) as a tolerable bridge to allogeneic transplantation for potential cure in this unfit patient, aligning with poor prognosis of t-MDS/AML and need to minimize toxicity before transplant. Main logical issue(s): none; the stem provides sufficient details to discriminate C as uniquely best, with alternatives inferior—A ignores myeloid progression, B risks excess toxicity from intensive induction, D is palliative without curative intent, E increases relapse/graft failure without cytoreduction. Main medical accuracy issue(s): none; consistent with NCCN/ELN guidelines for hypomethylating agent plus BCL2 inhibitor in adverse-risk AML/MDS, especially for bridging to allo-SCT in comorbid patients; avoids outdated intensive approaches. Minimal fix: none required, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include therapy-related MDS/AML with 18% blasts, multilineage dysplasia, complex cytogenetics (monosomy 7), HCT-CI score of 4 indicating moderate comorbidity risk, and availability of a matched unrelated donor. These support cytoreduction with azacitidine plus venetoclax (C) as a tolerable bridge to allogeneic transplantation for potential cure in this unfit patient, aligning with poor prognosis of t-MDS/AML and need to minimize toxicity before transplant. Main logical issue(s): none; the stem provides sufficient details to discriminate C as uniquely best, with alternatives inferior—A ignores myeloid progression, B risks excess toxicity from intensive induction, D is palliative without curative intent, E increases relapse/graft failure without cytoreduction. Main medical accuracy issue(s): none; consistent with NCCN/ELN guidelines for hypomethylating agent plus BCL2 inhibitor in adverse-risk AML/MDS, especially for bridging to allo-SCT in comorbid patients; avoids outdated intensive approaches. Minimal fix: none required, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130", "question_id": "20251223T225810101Z_gpt-5.1-2025-11-13_seed130-020", "question": "A 32-year-old man with long-standing severe atopic dermatitis refractory to topical steroids and cyclosporine is started on dupilumab (anti-IL-4Rα). After 5 months, his skin disease improves markedly, but he develops new-onset peripheral eosinophilia (AEC 3,000/µL), adult-onset asthma, and transient pulmonary infiltrates on CT. ANCA is negative, and biopsy of a skin nodule shows eosinophil-rich vasculitis of small vessels. Which immunologic mechanism best explains this paradoxical adverse event?", "options": ["Unopposed IL-5-mediated eosinophil proliferation due to blockade of IL-4/IL-13 signaling", "Expansion of Th17 cells with increased IL-17 production driven by IL-4 pathway inhibition", "Emergence of autoreactive B cells secondary to impaired regulatory T-cell differentiation", "Type I interferon upregulation resulting from altered JAK-STAT signaling downstream of IL-4Rα", "Loss of IL-31 signaling leading to compensatory mast cell activation and eosinophilia"], "answer": "A", "answer_index": 0, "explanation": "Dupilumab blocks IL-4/IL-13 signaling, which can shift the Th2 cytokine milieu and lead to relative dominance of IL-5-driven eosinophil proliferation and activation, precipitating eosinophilic vasculitis/EGPA-like syndromes in susceptible patients. Th17 expansion (B), autoreactive B cells via Treg failure (C), interferon upregulation (D), or IL-31/mast cell effects (E) do not directly account for marked eosinophilia and small-vessel eosinophilic vasculitis associated with IL-4Rα blockade.", "generator_model": "gpt-5.1-2025-11-13", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 32-year-old man with refractory atopic dermatitis on dupilumab (anti-IL-4Rα) develops marked improvement in skin disease but new peripheral eosinophilia (AEC 3,000/µL), adult-onset asthma, transient pulmonary infiltrates on CT, negative ANCA, and skin nodule biopsy showing eosinophil-rich small-vessel vasculitis. These findings suggest a dupilumab-induced EGPA-like syndrome or hypereosinophilic vasculitis, driven by unopposed IL-5 effects from IL-4/IL-13 blockade. The clinical problem asks for the immunologic mechanism behind this paradoxical adverse event. Keyed answer A fits precisely, as IL-4/IL-13 inhibition can lead to relative IL-5 dominance, promoting eosinophil proliferation and activation without requiring unstated assumptions. Alternatives: B is worse as Th17/IL-17 expansion doesn't explain eosinophilia or vasculitis; C fails to link to eosinophilic features via Treg impairment; D's IFN upregulation isn't a direct consequence of IL-4Rα blockade here; E misattributes to IL-31/mast cells, which aren't primarily affected. Main logical issue(s): None; stem allows clear discrimination of one best option. Main medical accuracy issue(s): None; aligns with reported dupilumab side effects in literature (e.g., eosinophilic pneumonia, vasculitis), consistent with current guidelines on biologic therapies for atopic conditions. Minimal fix: No edit required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 32-year-old man with refractory atopic dermatitis on dupilumab (anti-IL-4Rα) develops marked improvement in skin disease but new peripheral eosinophilia (AEC 3,000/µL), adult-onset asthma, transient pulmonary infiltrates on CT, negative ANCA, and skin nodule biopsy showing eosinophil-rich small-vessel vasculitis. These findings suggest a dupilumab-induced EGPA-like syndrome or hypereosinophilic vasculitis, driven by unopposed IL-5 effects from IL-4/IL-13 blockade. The clinical problem asks for the immunologic mechanism behind this paradoxical adverse event. Keyed answer A fits precisely, as IL-4/IL-13 inhibition can lead to relative IL-5 dominance, promoting eosinophil proliferation and activation without requiring unstated assumptions. Alternatives: B is worse as Th17/IL-17 expansion doesn't explain eosinophilia or vasculitis; C fails to link to eosinophilic features via Treg impairment; D's IFN upregulation isn't a direct consequence of IL-4Rα blockade here; E misattributes to IL-31/mast cells, which aren't primarily affected. Main logical issue(s): None; stem allows clear discrimination of one best option. Main medical accuracy issue(s): None; aligns with reported dupilumab side effects in literature (e.g., eosinophilic pneumonia, vasculitis), consistent with current guidelines on biologic therapies for atopic conditions. Minimal fix: No edit required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]